The IMCO 4T Device enables community health workers to perform accurate, multi-disease triage for TB, malaria, and neonatal sepsis — then monitor continuously through transport, so your clinical team knows what's coming before it arrives.
Designed from the ground up for community health workers in resource-limited settings — offline-first, solar-chargeable, and operable after 4 hours of training.
Not an equity add-on — a patient safety requirement for Nigerian clinical settings.
The 4T Device closes the data gap at every step of the patient journey.
This is a functional simulation of the 4T Device CHW workflow — from patient intake through vital sign capture, AI assessment, telemetry monitoring, and FHIR record export. Click through each step.
This simulation demonstrates the complete 4T Device CHW workflow including pre-hospital transport monitoring. Development prototype — Nigerian primary care CHW workflow.
We are seeking a Nigerian primary care or trauma facility as our Phase 3 clinical validation partner for a 500-patient study comparing 4T Device triage accuracy against physician gold-standard assessment.
We are not asking for a commitment. We are asking for 30 minutes to demonstrate the device, hear about your clinical context, and explore whether this technology could serve your team.
Reg Redmond · Founder & Executive Director · IMCO-NFP · Chicago, Illinois
IMAGEMEDIUM Consultants & Ombuds NFP · AISOTRAC Nigeria
Official terminology reference for clinical communications, regulatory submissions, and partner documentation.
Using IMCO 4T Device as the brand name while designating the overarching system a Modular Clinical Screening Platform positions it not just as a device, but as a scalable health infrastructure solution — ready for clinical deployment at population scale.
The offline-first, ruggedized Android tablet providing the voice-guided interface and WHO IMAI clinical logic. Designed for frontline community health workers in low-connectivity environments, it delivers structured clinical decision support at the point of first contact — producing a 5-level ESI acuity score and disease pathway flags across TB, malaria, and neonatal SIRS from symptom input alone.
The wearable sensor kit designed for single-action placement (<30 seconds). Streams six continuous vital sign parameters via BLE 5.0 to the Pre-Triage Module and — through mobile connectivity — to receiving clinical facilities during patient transport, enabling pre-arrival monitoring. Six parameters: SpO2 (with Fitzpatrick V–VI skin-tone correction), Heart Rate, Blood Pressure, Temperature, Respiratory Rate, and single-lead ECG. <85g · IP54 · 72-hour battery · zero consumables · zero cold-chain dependency.
| Term Type | Official Name | Description & Context |
|---|---|---|
| Brand Name | IMCO 4T Device | Primary commercial and clinical identifier for the system. Used in all external communications, regulatory submissions (FDA De Novo, NAFDAC Nigeria), labeling, and partner documentation. |
| 4T Acronym | Trauma · Telemetry · Triage · Treatment | Each letter maps to a clinical function: Trauma (point-of-contact assessment), Telemetry (continuous vital sign acquisition), Triage (AI-assisted acuity scoring), Treatment (WHO IMCI intervention-driven action prompts). |
| Platform Title | Modular Clinical Screening Platform | Descriptive proposal and regulatory title positioning the system as scalable health infrastructure rather than a single-point device solution. Used in Gates Foundation Grand Challenges submission. |
| Module 1 | Pre-Triage Module | Offline-first, ruggedized Android tablet with voice-guided WHO IMAI interface. Input/cognitive layer of the platform. Target unit cost: $50–75 at 500+ units. |
| Module 2 | Telemetry Triage Module | Wearable sensor kit for single-action placement. Six-parameter continuous acquisition: SpO2 (with Health Equity by Design Fitzpatrick V–VI correction), Heart Rate, Blood Pressure, Temperature, Respiratory Rate, single-lead ECG. Sensing layer of the platform. Target unit cost: $75 at 500+ units. |
| Design Principle | Health Equity by Design | The multi-wavelength PPG SpO2 correction system (green 530nm / red 660nm / IR 940nm + Fitzpatrick-stratified algorithm) addressing the 3–4× higher occult hypoxemia misread rate in Fitzpatrick V–VI patients. Documented by Sjoding et al., NEJM 2020. In Nigeria, a patient safety requirement — not an equity add-on. |
| Clinical Feature | Pre-Hospital Transport Monitoring | The Telemetry Triage Module operates autonomously after CHW attachment — streaming vital sign data continuously through patient transport to facility arrival. Receiving clinical teams see vital sign trends and alert status before the patient reaches the door. |
| AI Architecture | Three-Layer AI Decision Support | (1) Deterministic WHO/ESI rule-based clinical floor; (2) MIMIC-IV gradient-boosted triage model (~60,000 encounters); (3) disease-specific classifiers for TB, malaria, and neonatal SIRS. Human-in-the-loop mandatory — all outputs require clinician confirmation. |
Using IMCO 4T Device as the brand name while calling the overarching system a Modular Clinical Screening Platform positions it not just as a device, but as a scalable health infrastructure solution. The two-module architecture — a cognitive input layer (Pre-Triage Module) and a physiological sensing layer (Telemetry Triage Module) — enables independent upgrade paths, targeted procurement, and deployment flexibility across diverse clinical settings. The six-parameter telemetry suite, pre-hospital transport monitoring capability, and Health Equity by Design SpO2 correction are core architectural commitments that distinguish the 4T Device from every existing LMIC triage system at this price point.